Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders

Bibliography

• US approval for SB's Paxil. Scrip (1993) 1783:25.
   Google Scholar
• First launch for SmithKline Beecham (SB's) paroxet-ine. Scrip (1991) 1591:23.
   Google Scholar
• Paroxetine's first approval for panic. Scrip (1995) 2061:19.
   Google Scholar
• Paroxetine for obsessive compulsive disorder in the UK. Scrip (1995) 2072:30.
   Google Scholar
• Paroxetine approved for panic in UK. Scrip (1995) 2081:19.
   Google Scholar
• New US indication for Paxil. Scrip (1996) 2129:24.
   Google Scholar
• SmithKline Beecham's Seroxat approved in UK for SAD (social anxiety disorder). Scrip (1998) 2378:23.
   Google Scholar
• THOMAS DR, NELSON DR, AND JOHNSON AM: Bio-chemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine reuptake inhibitor. Psy-chopharmacology (1987) 93:193–200.
   PubMed Web of Science ®Google Scholar
• ••An excellent summary of the preclinical pharmacologicalprofile of paroxetine.
   Google Scholar
• MAGNUSSON I, TONDER K, ENGBAEK F: Paroxetine, a potent and selective long-acting inhibitor of synapto-somal 5-HT uptake in mice. J. Neural. Transm. (1982) 55:217–226.
   Web of Science ®Google Scholar
• HJORTH S, AUERBACH SB: 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake in-hibitors (SSRIs). Behav. Brain Res. (1996) 73:281–283.
   PubMed Web of Science ®Google Scholar
• HAJOS M, GARTSIDE SE, SHARP T: Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxet-ine. Naunyn Schmiedeberg's Arch. Pharmacol. (1995) 351:624–629.
   Google Scholar
• HJORTH S, AUERBACH SB: Further evidence for the im-portance of 5-HT1A autoreceptors in the action of se-lective serotonin reuptake inhibitors. Eur. J. Pharmacol. (1994) 260:251–255.
   PubMed Web of Science ®Google Scholar
• BUUS LASSEN J: Potent and long-lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur. J. Pharma-col. (1978) 47:351–358.
   PubMed Web of Science ®Google Scholar
• PLETSCHER A, LAUBACHER A: Blood platelets as a model for neurons: use and limitations. J. Neural. Trans. (1980) 16(1):7–16.
   Google Scholar
• DAPRADA M, CESURA AM, LAUNAY JM et al: Platelets as a model for neurones? Experientia (1988) 44:115–126.
   PubMedGoogle Scholar
• •A review of the utility of platelets as a model system for neu-rones; specific focus on the usefulness of platelets to study the serotonergic system.
   Google Scholar
• GENEFKE IK, GAREL A, MANDEL P: Factors influencing free serotonin in human plasma. Clin. Chem. Acta. (1968) 20:61–67.
   PubMed Web of Science ®Google Scholar
• SOMERVILLE BW: Platelet-bound and free serotonin levels in jugular and forearm venous blood during mi-graine. Neurology (1976) 26:41–45.
   PubMed Web of Science ®Google Scholar
• PETERSEN EN, BECHGAARD E, SORT WELL RJ etal.: Potent depletion of 5-HT from monkey whole blood by a new 5-HT uptake inhibitor, paroxetine (FG 7051). Eur. J. Pharmacol. (1978) 52:115–119.
   Google Scholar
• LUND J, LOMHOLT B, FABRICIUS J et al.: Paroxetine:pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta. Pharmacol Toxicol (1979) 44:289–295.
   PubMedGoogle Scholar
• MARSDEN CA, TYRER P, CASEY P et al.: Changes in hu-man whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxet-ine, a selective 5-HT uptake inhibitor. J. Psychopharma-col. (1987) 1:244–250.
   Google Scholar
• SCHLAKE HP, KUHS H, ROLF LH et al.: Platelet 5-HT trans-port in depressed patients under double-blind treat-ment with paroxetine. Acta. Psychiatr. Scand. (1989) 80(350149–151.
   Google Scholar
• DECHANT KL, CLISSOLD SP: Paroxetine. A review of itspharmacodynamic and pharmacokinetic properties, and therapeutic value in depressive illness. Drugs (1991) 41:225–253.
   Google Scholar
• BANERJEE SP, KING LS, RIGGI SJ et al.: Development ofbeta-adrenergic receptor subsensitivity by antidepres-sants. Nature (1977) 268:455–456.
   PubMed Web of Science ®Google Scholar
• VETULANI J, SULSER F: Action of various antidepressanttreatments reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature (1975) 257:495–496.
   PubMed Web of Science ®Google Scholar
• NELSON DR, THOMAS DR, JOHNSON AM: Pharmacologi-cal effects of paroxetine after repeated administration to animals. Acta. Psychiatr. Scand. (1989) 80 (350) :21–23.
   Google Scholar
• NELSON DR, PRATT GD, PALMER KJ et al.: Effect of par-oxetine, a selective 5-hydroxytryptamine uptake in-hibitor, on beta-adrenoceptors in rat brain: autoradiographic and functional studies. Neurophar-macology (1991) 30:607–616.
   PubMed Web of Science ®Google Scholar
• NELSON DR, PALMER KJ, JOHNSON AM: Effect of pro-longed 5-hydroxytryptamine uptake inhibition by paroxetine on cortical beta-1 and beta-2 adrenocep-tors in rat brain. Life ScL (1990) 47: 1683-1691.
   Google Scholar
• BYERLY WF, MCCONELL EJ, MCCABE RT et al.: Decreasedbeta-adrenergic receptors in rat brain after chronic ad-ministration of the selective serotonin reuptake in-hibitor fluoxetine. Psychopharmacology (1988) 94:141–143.
   PubMed Web of Science ®Google Scholar
• WONG DR, REID LR, BYMASTER FP et al: Chronic effectsof fluoxetine, a selective inhibitor of serotonin reup-take, on neurotransmitter receptors. J. Neural. Transm. (1985) 64:251–269.
   PubMed Web of Science ®Google Scholar
• CLAASSEN V: Review of the animal pharmacology andpharmacokinetics of fluvoxamine. Br. J. Clin. Pharma-col. (1983) 15(l):3495–3555.
   Google Scholar
• BENFIELD P, WARD A: Fluvoxamine: A review of thepharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs (1986) 32:313–334.
   PubMed Web of Science ®Google Scholar
• MISHRA R, JANOWSKY A, SULSER F: Subsensitivity of thenorepinephrine receptor-coupled adenylate cyclase system in brain: effects of nisoxetine versus fluoxet-ine. Eur. J. Pharmacol. (1979) 60:379–382.
   PubMed Web of Science ®Google Scholar
• NALEPA I, VETULANI J: Enhancement of the responsive-ness of corical adrenergic receptors by chronic ad-ministration of the 5-hydroxytryptamine uptake inhibitor citalopram. j Neurochem. (1993) 60:2029–2035.
   PubMedGoogle Scholar
• LUO H, RICHARDSON JS: A pharmacological compari-son of citalopram, a bicyclic serotonin selective up-take inhibitor, with traditional tricyclic antidepressants. Int. Clin. Psychopharmacol. (1993) 8:3–12.
   PubMed Web of Science ®Google Scholar
• HYTTEL J: Pharmacological characterization of selec-tive serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. (1994) 9(1):19–26.
   PubMedGoogle Scholar
• KOE BK: Preclinical pharmacology of sertraline: a po-tent and specific inhibitor of serotonin reuptake. J. Clin. Psych. (1990) 51(B):13–17.
   Google Scholar
• CHAPUT Y, deMONTIGNY C, BLIER P: Presynaptic andpostsynaptic modifications of the serotonin system by long-term administration of antidepressant treat-ments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology (1991) 5:219–229.
   PubMed Web of Science ®Google Scholar
• MCEVOY G : AMERICAN HOSPITAL FORMULARY SERV-ICE DRUG INFORMATION 98. American Society of Health-System Pharmacists (1998):1789–1794. A comprehensive overview of the kinetic, efficacy and safety of the tricyclic antidepressants.
   Google Scholar
• VOHRA J, HUNT D, BURROW G etal.: Intracardial defects following overdose of tricyclic antidepressant drugs. Eur.J. Cardiol (1975) 2:453–458.
   Google Scholar
• JEFFERSON JW: A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosomat. Med. (1975) 37:160–179.
   PubMed Web of Science ®Google Scholar
• JAKOBSEN J, HAUKSSON P, VESTERGAARD P: Heart rate variation in patients treated with antidepressants. Psy-chopharmacol. (1984) 84:544–548.
   PubMed Web of Science ®Google Scholar
• DORMAN T: Toxicity of tricyclic antidepressants: are there important differences? J. Int. Med. Res. (1985) 13:77–83.
   PubMed Web of Science ®Google Scholar
• ROBINSON DS, BARKER E: Tricyclic antidepressant car-diotoxicity. J. Am. Med. Assoc. (1976) 236:2089–2090.
   PubMed Web of Science ®Google Scholar
• BYREN JE, GOMOLL AW: Differential effects of trazo-done and imipramine on intracardial conduction in the anesthetized dog. Arch. Int. Pharmacodyn. Ther. (1982) 259:259–270.
   PubMedGoogle Scholar
• DHUMMAN-UPAKORN P, COBBIN LB: Cardiovascular ef-fects of amitriptyline in anesthetized dogs. Clin. Exp. Pharmacol. Physiol. (1977) 4:121–129.
   PubMed Web of Science ®Google Scholar
• DUMOVIC P, TRETHEWIE ER, BURROES G: The effects of tricyclic antidepressant drugs on the isolated perfused guinea pig heart. Clin. Exp. Pharmacol Physiol. (1977) 4:421–424.
   PubMed Web of Science ®Google Scholar
• LINDENFELD J, HORWITZ LD: Effects of amitriptyline on the left ventricular function in conscious dogs. J. Cardiovasc. Pharmacol (1981) 3:1221–1228.
   PubMed Web of Science ®Google Scholar
• MULLER J, SCHULZE S: Imipramine cardiotoxicity: an electrocardiographic and haemodynamic study in rabbits. Acta. Pharmacol. Toxicol. (1980) 46:191–199.
   PubMedGoogle Scholar
• BLACKWELL B: Antidepressant drugs. In: Side-effects of Drugs. Dukes MNG, Beeley L (Eds.), Elsevier, Amsterdam, Holland (1986):15–26.
   Google Scholar
• EDELSTEIN EL: Antidepressant drugs. In: Side-effects ofDrugs. Dukes MNG, Beeley L (Eds.), Excerpta Medica, Am-sterdam, Holland (1980):21–42.
   Google Scholar
• YOKOTA S, ISHIKURA Y, ONO H: Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imi-pramine, amitriptyline, and clomipramine. Jap. J. Pharmacol. (1987) 45:335–342.
   PubMedGoogle Scholar
• ••An excellent comparison of the cardiovascular effects of par-oxetine and several tricyclic compounds in dogs.
   Google Scholar
• HAMILTON TC, MORTON J, POYSER RH et al.: Compari- son of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneim.-Forch./Drug Res. (1986) 36:460–463.
   PubMed Web of Science ®Google Scholar
• WARRINGTON SJ, DANA-HAERI J, SINCLAIR AJ: Cardio-vascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and pla-cebo in healthy men. Acta. Psychiatr. Scand. (1989) 80(35042–44.
   Google Scholar
• RECHLIN T: The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. J. Clin. Psychopharmacol. (1994) 14:392–395.
   PubMed Web of Science ®Google Scholar
• ROOSE S, POLLOCK B, KENNEDY J et al.: Paroxetine inthe treatment of depressed patients with ischaemic heart disease. Biol. Psychiat. (1997) 42:243S.
   Google Scholar
• ROOSE SP, LAGHRISSI-THODE F, KENNEDY JS et al: Com-parison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. J. Am. Med. Assoc. (1998) 279:287–291.
   PubMed Web of Science ®Google Scholar
• •A well-done study comparing the cardiovascular toxicity profiles and efficacy of paroxetine and nortriptyline in de-pressed patients with ischemic heart disease.
   Google Scholar
• DEVANE CL: Pharmacokinetics of the selective sero- tonin reuptake inhibitors. J. Clin. Psychiatry (1992) 53 (2):13–20.
   PubMedGoogle Scholar
• CATTERSON ML, PRESKORN SH: Pharmacokinetics of selective serotonin reuptake inhibitors: clinical rele-vance. Pharmacol Toxicol (1996) 78:203–208.
   PubMedGoogle Scholar
• LEONARD BE: SSRI differentiation: pharmacology andpharmacokinetics. Hum. Psychopharmacol. (1995) 10(3):149–158.
   Google Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selectiveserotonin reuptake inhibitors. Clin. Pharmacokinet. (1993) 24:203–220.
   PubMed Web of Science ®Google Scholar
• KAYE CM, HADDOCK RE, LANGLEY PF et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta. Psychiatr. Scand. (1989) 80(35060–75.
   Google Scholar
• ••A comprehensive summary of the pharmacokinetics ofparoxetine.
   Google Scholar
• GREB WH, BRETT MA, BUSCHER HD et al.: Absorption ofparoxetine under various dietary conditions and fol-lowing antacid intake. Acta. Psychiatr. Scand. (1989) 80(35099–101.
   Google Scholar
• CREWE HK, LENNARD MS, TUCKER GT etal.: The effect ofselective serotonin re-uptake inhibitors on cyto-chrome P4502D6 (CYP2D6) activity in human liver mi-crosomes. Br. J. Clin. Pharmacol. (1992) 34:262–265.
   Google Scholar
• BLOOMER JC, WOODS FR, HADDOCK RE et al.: The roleof cytochrome P4502D6 in the metabolism of paroxet-ine by human liver microsomes. Br. J. Clin. Pharmacol. (1992) 33:521–523.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, BROSEN K, GRAM LF et al.: The relation-ship between paroxetine and sparteine oxidation polymorphism. Clin. Pharmac. Ther. (1992) 51:278–287.
   PubMed Web of Science ®Google Scholar
• BAYER AJ, ROBERTS NA, ALLEN EA et al: The pharma-cokinetics of paroxetine in the elderly. Acta. Psychiatr. Scand. (1989) 80(35085–86.
   Google Scholar
• DOYLE, GD, LAHER M, KELLY JG et al.: The pharmacoki-netics of paroxetine in renal impairment. Acta. Psychi-atr. Scand. (1989) 80(35089–90.
   Google Scholar
• KRASTEV Z, TERZIIVANOV D, VLAHOV V et al.: The phar-macokinetics of paroxetine in patients with liver cir-rhosis. Acta. Psychiatr. Scand. (1989) 80(35091–92.
   Google Scholar
• DALHOFF K, ALMDAL TP, BJERRUM K et al.: Pharmacoki-netics of paroxetine in patients with cirrhosis. Eur. Pharmacol. (1991) 41:351–354.
   Web of Science ®Google Scholar
• LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (1996) 11(5)31–61.
   Google Scholar
• HADDOCK RE, JOHNSON AM, LANGLEY PF et al: Meta-bolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its me-tabolites. Acta. Psychiatr. Scand. (1989) 80(35024–26.
   Google Scholar
• JEPPESEN U, GRAM LF, VISTISEN K eta].: Dose-dependent inhibition of CYP 1A2, CYP 2C19, and CYP 2D6 by cita-lopram, fluoxetine, fluvoxamine, and paroxetine. Eur. J. an. Pharmacol (1996) 51:73–78.
   Google Scholar
• BROSEN K, HANSEN JG, NIELSEN KK et al.: Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. (1993) 44:349–355.
   PubMed Web of Science ®Google Scholar
• ALBERS LJ, REIST C, HELMESTE D: Paroxetine shifts imi-pramine metabolism. Psychiat. Res. (1996) 59:189–196.
   PubMed Web of Science ®Google Scholar
• ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desi-pramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metaboliz-ers. j Clin. Psychopharmacol. (1997) 17:284–291.
   PubMed Web of Science ®Google Scholar
• LEINONEN E, KOPONEN HJ, LEPOLA U: Paroxetine in-creases serum trimipramine concentration. A report of two cases. Hum. Psychopharm. (1995) 10:345–347.
   Web of Science ®Google Scholar
• CENTORRINO F, BALDESSARINI RJ, FRAKENBURG FR et al: Serum levels of clozapine and norclozapine in pa-tients treated with selected serotonin reuptake inhibi-tors. Am. J. Psychiat. (1996) 153:820–822.
   PubMed Web of Science ®Google Scholar
• ANDERSON B, MIKKELSON M, VESTERAGER A et al.: Noinfluence of the antidepressant paroxetine on carba-mazepine, valproate, and phenytoin. Epilepsy Res. (1991) 10:201–204.
   PubMed Web of Science ®Google Scholar
• MALEK-AHMADI P, ALLEN SA: Paroxetine-molindone interaction. J. Clin. Psychiat. (1995) 56:82–83.
   PubMed Web of Science ®Google Scholar
• HORRIGAN JP, BARNHILL JP: Paroxetine-pimozide druginteraction. J. Am. Acad. Child Adolesc. Psychiatr. (1994) 33 :1060–1061.
   PubMed Web of Science ®Google Scholar
• FRANKLIN N, ODONTIADIS J, CLEMENT EM eta].: Suma-triptan in plasma by HPLC with coulometric detection: effect of paroxetine treatment on plasma sumatriptan concentrations. Eur. Neuropsychopharmacol (1996) 6(3)40.
   Google Scholar
• BLIER P, BERGERON R: The safety of concomitant use of sumatriptan and antidepressant treatments. J. Clin. Psychopharmacol (1995) 15:106–109.
   PubMed Web of Science ®Google Scholar
• LEUNG M, ONG M: Lack of an interaction between su-matriptan and selective serotonin reuptake inhibitors. Headache (1995) 35:488–489.
   PubMed Web of Science ®Google Scholar
• GUTHRIE SK, HARIHARAN M, KUMAR AA et al: Paroxet-ine effects on thiothixene pharmacokinetics. Pharmacol. Ther. (1996) 59:179.
   Google Scholar
• COOPER SM, JACKSON D, LOUDON JM et al.: The psycho-motor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alco-hol. Acta. Psychiatr. Scand. (1989) 80(35053–55.
   Google Scholar
• BANNISTER SJ, HOUSER VP, HULSE JD eta].: Evaluation of the potential for interactions of paroxetine with di-azepam, cimetidine, warfarin, and digoxin. Acta. Psy-chiatr. Scand. (1989) 80(350):102–106.
   Google Scholar
• BUDMAN CL, SHERLING M, BRUUN RD: Combined phar-macotherapy risk. J. Am. Acad. Child Adolesc. Psychiatry (1994) 34:263–264.
   Google Scholar
• GREB WH, BUSCHER G, DIERDORF H eta].: The effect ofliver enzyme inhibition by cimetidine and enzyme in-duction by phenobarbitone on the pharmacokinetics of paroxetine. Acta. Psychiatr. Scand. (1989) 80(35095–98.
   Google Scholar
• DUNNER D, KUMAR R: Paroxetine: A review of clinical experience. Pharmacopsychiatty (1998) 31:89–101.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the efficacy and safety ofparoxetine.
   Google Scholar
• GUNASEKARA NS, NOBLES, BENFIELD P: Paroxetine. An update of its pharmacology and therapeutic use in de-pression and a review of its use in other disorders. Drugs (1998) 55:85–120.
   Google Scholar
• ••A comprehensive review of the efficacy and safety ofparoxetine.
   Google Scholar
• CLAGHORN JL, KEIV A, RICKELS K et al.: Paroxetine ver- sus placebo: a double-blind comparison in depressed patients. J. Clin. Psychiatry (1992) 53:434–438.
   PubMed Web of Science ®Google Scholar
• ••The largest study in which paroxetine was compared di-rectly to placebo without use of a positive control.
   Google Scholar
• RICKELS K, AMSTERDAM J, CLARY C et al. A placebo- controlled, double-blind clinical trial of paroxetine in
   Google Scholar
• depressed outpatients. Acta. Psychiatr. Scand. (1989) 80:117–123.
   Google Scholar
• KIEV A: A double-blind placebo-controlled study of paroxetine in depressed outpatients. Proceedings of the 8th World Congress of Psychiatry. Athens, Greece. (Oct. 1989). Abstract.
   Google Scholar
• CLAGHORN JL: A double-blind comparison of paroxet-ine and placebo in the treatment of depressed outpa-tients. 16th CINP Congress. Munich, Germany (Aug. 1988). Abstract.
   Google Scholar
• HAMILTON M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry (1960) 23:56–62.
   PubMed Web of Science ®Google Scholar
• RASKIN A, SCHULTERBRANDT J, REATING, N eta].: Repli-cation of factors of psychopathology in interview, ward behavior, and self-reporting ratings of hospital-ized depressives. J. Nerv. Ment. Dis. (1969) 148:87–98.
   Google Scholar
• COVI L, RICKELS K, LIPMAN OS eta].: Effects of psycho-tropic agents on primary depression. Psychopharm. Bull. (1981) 17:100–103.
   Google Scholar
• ARMINEN S-L, IKONEN U, PULKKINEN P et al: A 12 week double-blind multi-centre study of paroxetine and imi-pramine in hospitalized depressed patients. Acta. Psy-chiatr. Scand. (1994) 89:382–389.
   PubMed Web of Science ®Google Scholar
• FEIGHNER JP, COHN JB, FABRE LF et al: A study compar-ing paroxetine, placebo, and imipramine in depressed patients. J. Affective Disorders (1993) 28:71–79.
   PubMed Web of Science ®Google Scholar
• ••A large comparison of paroxetine, placebo, and imipraminein depressed patients (same data appears in reference [123].
   Google Scholar
• OHRBERG S, CHRISTIANSEN PE, SEVERIN B et al.: Par-oxetine and imipramine in the treatment of depres-sive patients in psychiatric practice. Acta. Psychiatr. Scand. (1992) 86:437–444.
   PubMed Web of Science ®Google Scholar
• BIGNAMINI A, RAPISARDA V: A double-blind multicen-tre study of paroxetine and amitriptyline in depressed outpatients. Int. Clin. Psychopharmacol. (1992) 6(4)37–41.
   Google Scholar
• CHRISTIANSEN PE, BEHNKE K, BLACK CH et al.: Paroxet-ine and amitriptyline in the treatment of depression in general practice. Acta. Psychiatr. Scand. (1996) 93:158–163.
   PubMed Web of Science ®Google Scholar
• MOLLER H-J, BERZEWSKI H, ECKMANN F et al.: Double-blind multicenter study of paroxetine and amitrip-tyline in depressed inpatients. Pharmacopsychiatry (1993) 26:75–78.
   PubMed Web of Science ®Google Scholar
• STUPPAECK CH, GERETSEGGER C, WHITWORTH AB et al.: A multicenter double-blind trial of paroxetine ver-sus amitriptyline in depressed inpatients. J. Clin. Psy-chopharmacol. (1994) 14:241–246.
   PubMed Web of Science ®Google Scholar
• LAURSEN AL, MIKKELSEN PL, RASMUSSEN S et al.: Par-oxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta. Psychiatr. Scand. (1985) 71:249–255.
   PubMed Web of Science ®Google Scholar
• BASCARA L: A double-blind study to compare the effec-tiveness and tolerability of paroxetine and amitrip-tyline in depressed patients. Acta. Psychiatr. Scand. (1989) 80(350):141–142.
   Google Scholar
• RAVINDRAN AV, JUDGE R, HUNTER BN et al.: A double-blind multicenter study in primary care comparing paroxetine and clomipramine in patients with depres-sion and associated anxiety. J. Clin. Psychiatry (1997) 58:112–118.
   PubMed Web of Science ®Google Scholar
• •A comparison of the efficacy of paroxetine and clomi-pramine in the treatment of depression and anxiety in over 1000 patients.
   Google Scholar
• GUILLIBERT E, PELICIER Y, ARCHAMBAULT JC et al.: A double-blind multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta. Psy-chiatr. Scand. (1989) 80(350):132–134.
   PubMedGoogle Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Par-oxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. (1990) 18:289–299.
   PubMed Web of Science ®Google Scholar
• MOON C, VINCE M: Treatment of major depression in general practice: a double-blind comparison of par-oxetine and lofepramine. Br. J. Clin. Pract. (1996) 50:240–244.
   PubMedGoogle Scholar
• SCHNYDER U, KOLLER-LIESER A: A double-blind multi-centre study of paroxetine and maprotiline in major depression. Can. J. Psychiatry (1996) 41:239–244.
   PubMed Web of Science ®Google Scholar
• SZEGEDI H, WETZEL H, ANGERBACH D eta].: A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry (1997) 30:97–105.
   Google Scholar
• •A comparison of paroxetine and maprotiline in over 500 patients.
   Google Scholar
• KASAS A, REYNAERT C, LARULLE M et al.: A double-blind study of paroxetine and maprotiline in major depres-sion. Neuropsychopharmacology (1994) 11:274.
   Google Scholar
• DeWILDE J, SPIERS R. MERTENS C eta].: A double-blind, comparative, multicentre study comparing paroxet-ine with fluoxetine in depressed patients. Hosp. For-mul (1993) 28:36–40.
   Google Scholar
• ONTIVEROS A, GARCIA-BARRIGA C: A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br. J. Clin. Res. (1997) 8:23–32.
   Google Scholar
• TIGNOL J: A double-blind, randomized, fluoxetine-controlled multicenter study of paroxetine in the treatment of depression. J. Clin. Psychopharmacol. (1993) 13(2):18–22.
   Google Scholar
• GAGIANO CA: A double-blind comparison of paroxet-ine and fluoxetine in patients with major depression. Br. J. Clin. Res. (1993) 4:145–152.
   Google Scholar
• GERETSEGGER C, BOHMER F, LUDWIG M: Paroxetine in the elderly depressed patient: randomized compari-son with fluoxetine of efficacy, cognitive and behav-ioural effects. Int. Clin. Psychopharmacol (1994) 9:25–29.
   PubMed Web of Science ®Google Scholar
• ANSSEAU M, GABRIELS A, LOYENS J et al.: Controlled comparison of paroxetine and fluvoxamine in major depression. Hum. Psychopharm. (1994) 9:329–336.
   Web of Science ®Google Scholar
• KIEV A, FEIGER A: A double-blind comparison of fluvoxamine and paroxetine in the treatment of de-pressed outpatients. J. Clin. Psychiat. (1997) 58:146–152.
   PubMed Web of Science ®Google Scholar
• ZANARDI R, FRANCHINI L, GASPERINI M: Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am. J. Psychiat. (1996) 153:1631–1633.
   PubMed Web of Science ®Google Scholar
• BALDWIN DS, HAWLEY CH, ABED RT etal.: A multicenter double-blind comparison of nefazodone and paroxet-ine in the treatment of outpatients with moderate-to-severe depression. J. Clin. Psychiat. (1996) 57(2):46–52.
   Google Scholar
• DUNBAR GC, COHN JB, FABRE LF et al.: A comparison of paroxetine, imipramine, and placebo in depressed pa-tients. Br. J. Psychiat. (1991) 159:394–398.
   PubMed Web of Science ®Google Scholar
• ••A large comparison of paroxetine, placebo, and imipraminein depressed patients (same data appears in reference [99]).
   Google Scholar
• MONTGOMERY SA, ASBERG M: A new depression rating scale designed to be sensitive to change. Br. J. Psychiat. (1979) 134:382–389.
   PubMed Web of Science ®Google Scholar
• SNAITH RP, BAUGH SJ, CLAYDEN AD et al.: The Clinical Anxiety Scale: an instrument derived from the Hamil-ton Anxiety Scale. Br. J. Psychiat. (1982) 141:518–523.
   PubMed Web of Science ®Google Scholar
• COHEN GD: Prevalence of psychiatric problems in older adults. Psychiat. Ann. (1990) 20:433–438.
   Web of Science ®Google Scholar
• KANOWSKI S: Age-dependent epidemiology of depres-sion. Gerontol. (1990) 40 (6) :3–11.
   Google Scholar
• DUNNER DL, COHN JB, WALSHE T et al.: Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J. Psychiat. (1992) 53:57–60.
   Google Scholar
• •A comparison of paroxetine and doxepin in elderly de-pressed patients.
   Google Scholar
• DORMAN T: Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int. Clin. Psy-chopharmacol. (1992) 6(4):53–58.
   PubMedGoogle Scholar
• GERETSEGGER C, STUPPAECK CH, MAIR M et al: Multi-center double-blind study of paroxetine and amitrip-tyline in elderly depressed inpatients. Psychopharmacology (1995) 119:277–281.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON DR, TONG S, MOON C et al.: A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in de-pressed elderly patients. Br. J. Clin. Res. (1991) 2:43–57.
   Google Scholar
• SCHONE W, LUDWIG M: A double-blind study of par-oxetine compared with fluoxetine in geriatric patients with major depression. J. Clin. Psychopharmacol. (1993) 13(2)34–39.
   Google Scholar
• MONTGOMERY SA, DUNBAR G: Paroxetine is better than placebo in relapse prevention and the prophy-laxis of recurrent depression. Int. Clin. Psychopharma-col. (1993) 8:189–195.
   PubMed Web of Science ®Google Scholar
• •Long-term randomised evaluation of the continued efficacy of paroxetine vs. placebo in patients shown to respond to the SSRI in an open study.
   Google Scholar
• CLAGHORN JL, FEIGHNER JP: A double-blind compari-son of paroxetine with imipramine in the long-term treatment of depression. J. Clin. Psychopharmacol. (1993) 13(2):23–27.
   Google Scholar
• ••Long-term (1 year) double-blind placebo-controlledfollow-up of the efficacy of paroxetine.
   Google Scholar
• MINDHAM RHS, HOWLAND 0, SHEPHERD M: An evalua-tion of continuation therapy with tricyclic antidepres-sants in depressive illness. Psycho]. Med. (1973) 3:5–17.
   PubMed Web of Science ®Google Scholar
• KLEIN DF, FINK F: Psychiatry reaction pattern to imi-pramine. Am. J. Psychiat. (1962) 119:432–438.
   PubMed Web of Science ®Google Scholar
• KLEIN DF: Delineation of two drug-responsive anxiety syndromes. Psychopharmacology (1964) 5:397–408.
   PubMed Web of Science ®Google Scholar
• KLEIN DF: The importance of psychiatric diagnosis in prediction of clinical drug effects. Arch. Gen. Psychiat. (1967) 16:118–126.
   PubMed Web of Science ®Google Scholar
• DEN BOER JA, WESTENBERG HGM, KAMERBECK WDJ et al.: Effect of serotonin uptake inhibitors in anxiety dis-orders: a double-blind comparison of clomipramine and fluvoxamine. Int. Clin. Psychopharmacology. (1987) 2:21–32.
   PubMed Web of Science ®Google Scholar
• EVANS L, KENARDY J, SCHNEIDER P et al.: Effect of a se-lective serotonin uptake inhibitor in agoraphobia with panic attacks. A double blind comparison of zi-melidine, imipramine, and placebo. Acta. Psychiatr. Scand. (1986) 73:49–53.
   PubMed Web of Science ®Google Scholar
• BLACK DW, WESNER R, BOWERS W et al.: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch. Gen. Psychiat. (1993) 50:44–50.
   PubMed Web of Science ®Google Scholar
• HOEHN-SARIC R, MCLEOD DR, HIPSLEY PA: Effect of fluvoxamine in panic disorder. J. Clin. Psychopharma-col . (1993) 13:321–326.
   PubMed Web of Science ®Google Scholar
• OEHRBERG S, CHRISTIANSEN PE, BEHNKE K et al.: Par-oxetine in the treatment of panic disorder. A random-ized, double-blind, placebo controlled study. Br. J. Psychiat. (1995) 167:374–379.
   Google Scholar
• LECRUBIER Y, BAKKER A, DUNBAR G et al.: A compari-son of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta. Psychiat. Scand. (1997) 95:145–152.
   PubMed Web of Science ®Google Scholar
• LECRUBIER Y, JUDGE R: Long term evaluation of par-oxetine, clomipramine, and placebo in panic attack. Acta. Psychiatr. Scand (1997) 95:153–160.
   PubMed Web of Science ®Google Scholar
• •Long-term evaluation of the efficacy of paroxetine in panic disorder.
   Google Scholar
• BALLENGER JC, WHEADON DE, STEINER M et al.: Double-blind, fixed dose, placebo- controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiat. (1998) 155:36–42.
   PubMed Web of Science ®Google Scholar
• ••Fixed dose evaluation of paroxetine in the treatment ofpanic disorder.
   Google Scholar
• FLAMENT M, WHITAKER A, RAPOPORT J: Obsessive com-pulsive disorder in adolescence. J. Am. Acad. Child Ado-lesc. Psychiat. (1988) 27:764–771.
   PubMed Web of Science ®Google Scholar
• VALLENI-BASILE AL, GARRISON CZ, JACKSON KL et al.: Frequency of obsessive-compulsive disorder in a com-munity sample of young adolescents. J. Am. Acad. Child Adolesc. Psychiat. (1994) 33:782–791.
   PubMed Web of Science ®Google Scholar
• HANNA GL: Demographic and clinical features of obsessive-compulsive disorder in children and adoles-cence. J. Am. Acad. Child Adolesc. Psychial (1995) 34:19–27.
   PubMed Web of Science ®Google Scholar
• PAULS DL, ALSOBROOK JP, PHIL M et al.: A family study of obsessive-compulsive disorder. Am. J. PsychiaL (1995) 152:76–84.
   PubMed Web of Science ®Google Scholar
• ALSOP M, VERDUYN C: A follow-up of adolescents with obsessive compulsive disorder. Br. J. Psychial (1988) 154:829–834.
   Web of Science ®Google Scholar
• BERG CZ, RAPOPORT JL, WHITAKER A et al: Childhood obsessive compulsive disorder: a two year prospective follow-up of a community sample. J. Am. Acad. Child Adolesc. PsychiaL (1989) 28:528–533.
   PubMed Web of Science ®Google Scholar
• WEVER C, REY JM: Juvenile obsessive-compulsive disor-der. Austr. New Zealand J. PsychiaL (1997) 31:105–113.
   PubMed Web of Science ®Google Scholar
• FIGUEROA YM, ROSENBERG DR, BIRMAHER B et al: Combination treatment with clomipramine and selec-tive serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J. Child Adol. Psychopharmacol (1998) 8:61–67.
   PubMed Web of Science ®Google Scholar
• MOORE GJ, MacMASTER FP, STEWART RNC et al: Case study: Caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. PsychiaL (1998) 37:663–667.
   PubMed Web of Science ®Google Scholar
• MUNDO E, BIANCHI L, BELLODI L: Efficacy of fluvoxam-ine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single blind study. J. Clin. Psychopharmacol. (1997) 17:267–271.
   PubMed Web of Science ®Google Scholar
• BLACK DW, MONAHAN MA, GABLE J et al.: Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J. Gun. Psychiat. (1998) 59:420–425.
   Google Scholar
• ZOHAR J, JUDGE R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychial (1996) 169:468–474.
   Web of Science ®Google Scholar
• ••Placebo-controlled evaluation of paroxetine and clomi-pramine in obsessive-compulsive disorder.
   Google Scholar
• GOODMAN WK, PRICE LH, RASMUSSEN SA et al: The Yale-Brown Obsessive Compulsive Scale. Arch. Gen. Psychial (1989) 46:1006–1016.
   PubMed Web of Science ®Google Scholar
• DUNBAR G, STEINER M, BUSHNELL WD et al.: Long-term treatment and prevention of relapse of obsessive com-pulsive disorder with paroxetine. Eur. Neuropsycho-pharmacol. (1995):372.
   Google Scholar
• RINGOLD AL: Paroxetine efficacy in social phobia. J. Clin. Psychial (1994) 55:363–364.
   PubMed Web of Science ®Google Scholar
• MANCINI C, VAN AMERINGEN M: Paroxetine in social phobia. J. Clin. PsychiaL (1996) 57:519–522.
   PubMed Web of Science ®Google Scholar
• BERK M: Fluoxetine and social phobia. J. Clin. PsychiaL (1995) 56:36–37.
   PubMed Web of Science ®Google Scholar
• BLACK B, UHDE TW, TANCER ME: Fluoxetine for the treatment of social phobia. J. Clin. Psychopharmacol. (1992) 12:293–295.
   PubMed Web of Science ®Google Scholar
• SCHNEIER FR, CHIN SJ, HOLLANDER E. et al.: Fluoxetine in social phobia. J. Clin. Psychopharmacol. (1992) 12:62–64.
   PubMed Web of Science ®Google Scholar
• STERNBACH H: Fluoxetine treatment of social phobia. J. Clin. Psychopharmacol. (1990) 10:230–231.
   PubMed Web of Science ®Google Scholar
• VAN AMERINGEN M, MANCINI C, STREINER DL: Fluoxet-ine efficacy in social phobia. J. Clin. Psychial (1993) 54:27–32.
   PubMed Web of Science ®Google Scholar
• KATZELMICK DJ, KOBAK KA, GREIST JH et al.: Sertraline for social phobia: a double-blind placebo-controlled crossover study. Am. J. Psychial (1995) 152:1368–1371.
   PubMed Web of Science ®Google Scholar
• VAN VLIET IM, DEN BOER JA, WESTENBERG HGM: Psy-chopharmacological treatment of social phobia: A double-blind placebo-controlled crossover study. Am. PsychiaL (1995) 152:1368–1371.
   PubMedGoogle Scholar
• STEIN MB, CHARTIER MJ, HAZEN AL et al.: Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled dis-continuation. J. Clin. Psychopharmacol. (1996) 16:218–222.
   PubMed Web of Science ®Google Scholar
• GERGEL I, PITTS C, OAKES R. et al: Significant improve-ment in symptoms of social phobia after paroxetine treatment. Biol. PsychiaL (1997) 42(0:26. STEIN MB, LIEBOWITZ MR, LYDIARD BR et al.: Paroxet-ine treatment of generalized social phobia (social anxiety disorder). J. Am. Med. Assoc. (1998) 280:708-713. First multicentre double-blind randomised study of an SSRI as treatment for social anxiety disorder. LIEBOWITZ MR: Social phobia. In: Modern problems of pharmacopsychiatty. Ban Ta, Pichot P, Poldinger W (Eds.), Karger, New York, USA (1987):152.
   Google Scholar
• ERIKSSON E, HEDBERG MA, ANDERSCH B et al.: The sero-tonin reuptake inhibitor paroxetin (sp) is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsycho-pharmacology (1995) 12:167–176.
   PubMed Web of Science ®Google Scholar
• YONKERS KA, GUILLION C, WILLIAMS A et al.: Paroxetine as a treatment for premenstrual dysphoric disorder. J. Clin. Psychopharmacol (1996) 16:3–8.
   PubMed Web of Science ®Google Scholar
• LANDMARK M, OLESEN J: Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache (1994) 34:20–24.
   Google Scholar
• FOSTER CA, BAFALOUKOS J: Paroxetine in the treat-ment of chronic daily headache. Headache (1994) 34:587–589.
   PubMed Web of Science ®Google Scholar
• SIDRUP SH, GRAM LF, BROSEN K et al.: The selective se-rotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain (1990) 42:135–144.
   PubMed Web of Science ®Google Scholar
• MARSHALL RD, SCHNEIER FR, FALLON BA et al: An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol (1998) 18:10–18.
   PubMed Web of Science ®Google Scholar
• LUDOVICO GM, CORVASCE A, PAGLIARULO G et al.: Par-oxetine in the treatment of premature ejaculation. Br. Urol (1996) 77:881–882.
   PubMedGoogle Scholar
• WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH: Paroxetine treatment of premature ejaculation: a double-blind randomized placebo-controlled study. Am. J. Psychiat. (1994) 151:1377–1379.
   PubMed Web of Science ®Google Scholar
• WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH: Ejaculation-retarding properties of paroxetine in pa-tients with primary premature ejaculation: a double-blind, randomized dose-response study. Br. J Urol. (1997) 79:592–595.
   PubMedGoogle Scholar
• LEYMAN S, MATTELAER PM, VAN STEENBERGE I et al: Paroxetine: post-marketing experience on 4024 de-pressed patients in Belgium. Eur. j Clin. Res. (1995) 7:287–296.
   Google Scholar
• •Summary of a large post marketing study with paroxetine.
   Google Scholar
• INMAN W, KUBOTA K, PEARCE G et al: PEM report number 6: Paroxetine. Pharmacoepidemiol Drug Sat'. (1993) 2:393–422.
   Google Scholar
• MONTEJO-GONZALEZ AL, LIORCA G, IZQUIERDO JA et SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospec-tive, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. (1997) 23:176–194.
   PubMed Web of Science ®Google Scholar
• ZAJECKA J, MITCHELL S, FAWCETT J: Treatment-emergent changes in sexual function with selective se-rotonin reuptake inhibitors as measured with the Rush Sexual Survey. Psychopharm. Bull. (1997) 33:755–760.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, ROBERTS A: SSRIs: well tolerated treatment for depression. Hum. Psychopharmacol. (1994) 9(0:7–10.
   Google Scholar
• KULIN NA, PASTUSZAK A, SAGE SR et al: Pregnancy out-come following maternal use of new selective sero-tonin reuptake inhibitors. J. Am. Med. Assoc. (1998) 279:609–610.
   PubMed Web of Science ®Google Scholar
• BOYER WF, BLUMHARDT CL: The safety profile of par-oxetine. j Clin. PsychiaL (1992) 53:61-66. William E Heydorn, Forest Laboratories, 909 Third Avenue, New York, NY 10022–4731, USA Tel.: +1 212 224 6642; Fax: +1 212 750 9152; Email: [email protected]
   Google Scholar